Tests in 240 cancer cell lines revealed a broad and selective anticancer activity of ACBI3 for cell lines bearing KRAS mutations vs. WT KRAS cell lines (IC50 = 478 nM vs. 8.3 μM, respectively). The gene discussed is KRAS; the disease is cancer.